Onconic Therapeutics said it will hold an extraordinary general meeting of shareholders on November 26, 2026 to handle amendments to its articles of incorporation and the election of outside directors and audit committee members.

The company said its board of directors resolved on October 16, 2026 to convene the extraordinary general meeting of shareholders. The meeting will address the partial amendment to the articles of incorporation along with the election of candidates Park Young-jae and Lee Kyung-min as outside directors and audit committee members. The company said the agenda item concerning Lee Kyung-min is conditional on approval of employment by the Public Official Ethics Committee (November 20, 2026), and that if such approval is not granted, the item will not be put to a vote.

1. 01

   The extraordinary general meeting of shareholders is scheduled for November 26, 2026 09:00 at the 12th floor grand auditorium of Jeil Pharma Holdings, 343 Sapyeong-daero, Seocho-gu, Seoul.

2. 02

   The agenda items are a partial amendment to the articles of incorporation (expanding the number of board seats), the election of independent director Park Young-jae (who will also serve as an audit committee member), the election of independent director Lee Kyung-min (a new appointment), and the election of Lee Kyung-min as an audit committee member.

3. 03

   Agenda items 3 and 4 (concerning candidate Lee Kyung-min) will be put to a vote subject to approval of employment by the Public Official Ethics Committee (November 20, 2026), and the company plans not to vote on them if such approval is not obtained.

4. 04

   Both candidates, Park Young-jae and Lee Kyung-min, are subject to new appointment for terms of 3 years.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Extraordinary general meeting date

November 26, 2026 09:00

Record date for voting rights

November 2, 2026

Board resolution date (decision date)

October 16, 2026

Outside directors attending / absent

2 / 0 persons

Scheduled date of employment approval (condition)

November 20, 2026

Filing facts

Filing type

Shareholders Meeting

Report name

Resolution to Convene a Shareholders Meeting (Extraordinary General Meeting)

Filed

Oct 16, 2026

Receipt number

20261016900750